| Revenue Growth | U.S. revenue $72M (up 19%); International revenue $11.1M (up 25%). |
|---|---|
| Mgmt Confidence | Increased conviction in full-year guide following strong Q1 system pricing performance. |
| Demand Visibility | U.S. capital pipeline building; UK pipeline growing nicely following Hydros launch. |
| Margin Trends | Gross margin 65%; expected to exit Q4 2026 at 66% plus. |
| Op. Leverage | Improving leverage of cost structure and overhead absorption as revenue scales. |
| Pricing Power | Record U.S. system ASP of $485,000; handpiece ASP up 10% YoY. |
| Vol vs Price | Growth driven by 30% procedure volume and 14% sequential system price increase. |
| Segment Growth | U.S. systems revenue grew 25%; U.S. handpieces/consumables grew 13%. |
| New Clients | Sold 49 Hydros systems; 7 new systems in UK NHS hospitals. |
| Capex & Debt | $249M cash on hand; no new debt or M&A mentioned. |
| Regulatory | FDA clearance for Second Gen First Assist AI software; EAU guideline upgrade. |
| Commentary | Focusing on 'price discipline' and 'launch teams' to ensure long-term profitability. |
| New Launches | International Hydros launch in UK; Second Generation First Assist AI software. |
Growth
Total revenue $83.1M (up 20%); U.S. procedures grew 30% to 12,200 units.
Outlook
Full-year 2026 revenue $390M-$410M; positive adjusted EBITDA expected by Q4 2026.
Risks
Management pivoted on Q2 procedure specifics, citing 'normal seasonality' and 'short-term disruption' from sales realignment.
The company's earnings call, NASDAQ: PRCT, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Procept BioRobotics Corp: key numbers
- Share price
- $23.54Close, Nov 16
- Market cap
- $1.35B
- Shares outstanding
- 57.54MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Procept BioRobotics Corp
All →Procept BioRobotics Chief Strat/Marketing Officer Pooja Sharma Sells $92.9K of Stock
Pooja Sharma, Chief Strat/Marketing Officer, sold 4,710 shares of Procept BioRobotics Corp at $19.71 a share, worth $92.9K in total on Nov 6, 2026. Shares held after the trade: 106,471 (-4.2%).
- Value
- $92.9K
- Shares
- 4,710
- Price
- $19.71
- Role
- Chief Strat/Marketing Officer
- Holding change
- -4.2%
- Trade date
- Nov 6, 2026
Procept BioRobotics Q3 2026 Results: Net Loss of $26.5M, Loss Widens
For the quarter ended September 30, 2026, PROCEPT BioRobotics reported revenue of $98.3 million, a 18% increase compared to the same period in 2025. Despite the revenue growth, the company reported a net loss of $26.5 million for the quarter, driven by increased selling, general, and administrative expenses.
- Key figure
- Net loss $26.5M
Procept BioRobotics Financial Results
PROCEPT BioRobotics reported Q3 2026 total revenue of $98.3 million, an increase of 18% year-over-year, driven by strong U.S. procedure growth and the rollout of its HYDROS systems. The company reported a net loss of $26.5 million for the quarter while reaffirming its full-year 2026 revenue guidance of $390 million to $410 million.
- Term
- Q3 2026
“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan. Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027. We see significant opportunity and a clear path to achieving durable growth and profitability ahead.”
Larry Wood, Chief Executive Officer
“This quarter, we continued expanding our installed base and drove strong utilization in HYDROS® accounts. We delivered approximately 18% revenue growth and 22% U.S. procedure growth while accelerating our replacement cycle to transition AquaBeam systems to HYDROS.”
Larry Wood, Chief Executive Officer
Procept BioRobotics Leadership Change
PROCEPT BioRobotics Corporation has expanded its board of directors from nine to ten members and appointed Dr. Michael Mack as a new independent Class II director, effective October 2, 2026. Dr. Mack, a highly published cardiac surgeon and healthcare executive, will serve until the 2029 annual meeting of stockholders. He will receive compensation consistent with the company's existing non-employee director program.
Procept BioRobotics Debt Financing Update with Canadian Imperial Bank of Commerce
PROCEPT BioRobotics Corporation entered into a third amendment to its existing Loan and Security Agreement with CIBC. The amendment extends the maturity date of the term loan by 12 months, from October 1, 2027, to October 1, 2028.
- Counterparty
- Canadian Imperial Bank of Commerce
- Term
- through Oct 2028